NCT07271615Completed
Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting
Preoperative Stellate Ganglion Block Reduce the Incidence of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Prospective, Randomized Controlled Pilot Trial
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 26 Nov 2025
- Start date
- 19 Nov 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Xijing Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT07271615
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 19 Nov 2025 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior cardiac surgery or atrial fibrillation ablation;
- Concomitant cardiac procedures (e.g., congenital heart disease repair, left ventricular reconstruction, valve surgery, or aortic surgery);
Other illness
- History of atrial fibrillation (defined as a supraventricular tachyarrhythmia characterized by rapid and irregular atrial electrical activity);
- Significant mitral valve disease (mitral valve area \<1.5 cm² or regurgitant jet area \<4 cm²), significant aortic valve disease (valve area \<1.5 cm² or regurgitant jet-to-left ventricular outflow tract ratio \>25%);
- Conditions requiring radiotherapy, chemotherapy, or long-term hormonal therapy;
Lab values
- Left ventricular ejection fraction (LVEF) \<35%;
Other
- Emergency coronary artery bypass grafting (CABG);
- Critical preoperative status requiring mechanical or pharmacological support before CABG;
- Severe left atrial enlargement (left atrial anteroposterior diameter \>55 mm);
- Poorly controlled hyperthyroidism;
- Patients with known clinical contraindications to stellate ganglion block (SGB).
Who the study is looking for
- more than 18 years old
- undergoing CABG
- Provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xijing hospital Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.